TCGA-GC-A3OO-01A-11R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.80157687
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.470
- MITOTIC_SPINDLE+0.420
- ESTROGEN_RESPONSE_EARLY+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- MYOGENESIS+0.350
- PROTEIN_SECRETION+0.340
- ANDROGEN_RESPONSE+0.330
- APICAL_JUNCTION+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- HEME_METABOLISM+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.430
- MYC_TARGETS_V1-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.250
- OXIDATIVE_PHOSPHORYLATION-0.240
- ALLOGRAFT_REJECTION-0.210
- PANCREAS_BETA_CELLS-0.180
- SPERMATOGENESIS-0.150
- INTERFERON_ALPHA_RESPONSE-0.130
- MTORC1_SIGNALING-0.080
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1023 | — | — | 0.766 |
| 2 | MNG1234 | — | — | 0.757 |
| 3 | MNG1012 | — | — | 0.739 |
| 4 | TCGA-BH-A18F-01A-11R-A12D-07 | — | A | 0.735 |
| 5 | TCGA-R3-A69X-01A-22R-A30C-07 | — | — | 0.732 |
| 6 | TCGA-AO-A0JA-01A-11R-A056-07 | — | A | 0.716 |
| 7 | SRR10900549 | — | — | 0.716 |
| 8 | TCGA-B6-A0RI-01A-11R-A056-07 | — | B | 0.713 |
| 9 | TCGA-86-6562-01A-11R-1755-07 | — | cohortA1 | 0.712 |
| 10 | TCGA-A1-A0SJ-01A-11R-A084-07 | — | B | 0.708 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.420 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.310 | Temsirolimus | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |